Multiple Myeloma Regression Mediated by Bruceantin

• Published in: Clinical cancer research Vol. 10; no. 3; pp. 1170 - 1179
• Main Authors: Cuendet, Muriel, Christov, Konstantin, Lantvit, Daniel D., Deng, Yunfan, Hedayat, Samad, Helson, Lawrence, McChesney, James D., Pezzuto, John M.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.02.2004
• Subjects: Animals; Antineoplastic agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Biological and medical sciences; Carbocyanines - pharmacology; Carrier Proteins - metabolism; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Caspases - metabolism; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Fluorescent Dyes - pharmacology; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Medical sciences; Membrane Potentials; Mice; Mice, SCID; Mitochondria - pathology; Models, Chemical; Multiple Myeloma - drug therapy; Neoplasm Transplantation; Pharmacology. Drug treatments; Poly(ADP-ribose) Polymerases - metabolism; Propidium - pharmacology; Proto-Oncogene Proteins c-myc - metabolism; Quassins - chemistry; Quassins - pharmacology; Tumors; Regression; Immunopathology; Malignant hemopathy; Immunoglobulinopathy; Myeloma; Lymphoproliferative syndrome
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-0362-3

Purpose: Bruceantin has been shown to induce cell differentiation in a number of leukemia and lymphoma cell lines. It also down-regulated c-MYC, suggesting a correlation of down-regulation with induction of cell differentiation or cell death. In the present study, we focused on multiple myeloma, using the RPMI 8226 cell line as a model. Experimental Design: The effects of bruceantin on c-MYC levels and apoptosis were examined by immunoblotting, 4′,6-diamidino-2-phenylindole staining, evaluation of caspase-like activity, and 3,3′-dihexyloxacarbocyanine iodide staining. The potential of bruceantin to inhibit primary tumor growth was assessed with RPMI 8226 xenografts in SCID mice, and apoptosis in the tumors was evaluated by the terminal deoxynucleotidyl transferase-mediated nick end labeling assay. Results: c-MYC was strongly down-regulated in cultured RPMI 8226 cells by treatment with bruceantin for 24 h. With U266 and H929 cells, bruceantin did not regulate c-MYC in this manner. Apoptosis was induced in the three cell lines. In RPMI 8226 cells, apoptosis occurred through proteolytic processing of procaspases and degradation of poly(ADP-ribose) polymerase. The mitochondrial pathway was also involved. Because RPMI 8226 cells were the most sensitive, they were used in a xenograft model. Bruceantin treatment (2.5–5 mg/kg) resulted in a significant regression of tumors without overt toxicity. Apoptosis was significantly elevated in tumors derived from animals treated with bruceantin (37%) as compared with the control tumors (14%). Conclusions: Bruceantin interferes with the growth of RPMI 8226 cells in cell culture and xenograft models. These results suggest that bruceantin should be reinvestigated for clinical efficacy against multiple myeloma and other hematological malignancies.